The analysis of secondary end-points indicates that simvastatin was associated with reductions in the incidence of non-fatal myocardial infarction absolute risk reduction of 2.1%, stroke (absolute risk reduction of 1.4%), and revascularisation (absolute risk reduction of 2.56%).